Attachment
Chairman Paul Letter to DNI Gabbard, p.41 · letter_dni:exh:00032
Page text: p.41 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
- Topics
- Therapeutics and treatments
Therapeutic Interventions
* No approved drugs, immune therapeutics and vacc
against any group 2b coronavirus
* Experimental Drugs (nsp12-RdRp target)
-- Remdesivir-ribonucleoside inhibitor
-- EIDD-1931-(b-D-N*-hydroxycytidine)-ribonucleoside inhibito
-- Combination lopinavir, ritonavir, and interferon beta again
-- Therapeutic antibodies (MERS-CoV)
Conservation of key RdRp motif residues
Motif G
Motif F
Motif A
Motif B
Motif C
M
Positioning of the
Nucleotide binding
Nucleotide binding.
Nucieotige binding
tit an
Stabiliz
5S template strand
Doty!
active ste
PDCOV DKSAGYPFUKLGK LKYAISARDRARTVAGY PILVOWDYPKCDRSM COTSSCDATIAYANSVENILQVVSANVATELST FOLMILSDDOVACID AKAGAVADL
229E NKSAGWPLNKFGK LKYAISGKERARTVOGV PKLMGWDYPKCDRAM GOTTSGDATTAYANSVENIFQAVSSNINCVLSV FSMMILSDOGVVCYN ABLGYIADI
NL63 DKSAGYPFNKFGK LKYAISAKNRARTVAGY PVLMGWDYPKCDRAM GGTSSGDATTAFANSVENICQAVSANVCALMSC FSMMILSDDGVYCYN ASKGYIANIS
0C43 DKSAGYPFNKPGR LKYAISAKNRARTVAGY PVLMGWDYPKCDRAM GGTSSGDAPTAPANEVPNICQAVSANVCALMSC PSMMILSDOGVVCYN ASKGY IANT
MHV DKSAGYPFNKFGK LKYAISAKNRARTVAGY PVLMGWDY PKCDRAM GGTSSGOATTAPANSVPNICQAVSANVCSLMAC FSMMILSDDGVVCYN ASKGY IANIS
KU] DKSAGYPFNKFGK LEYAISAKNRARTVAGV PVLMGWDYPKCORAM GGTSSGOATTAFANSVENICQAVTANVCSLMAC FSMMILSDDGVVCYN ASKGYIANIS
MERS DKSAGHPFNKFGK LKYAISAKNRARTVAGV PHLMGWDYPRCDRAM GGTSSGDATTAYANSVENILOATTANVSALMGA
ILSDDGVVCYN AAKGYIAGI
HKU9-4 DKSAGFPFNKFGK LKYAISAKNRARTVAGY PHLMGNDYPKCDRAM GGTSSGDSTTAYANSVFNICQAVSANLNTP!
ILSDDGVVCYN AQKGYVADI
nCoV-2019 DKSAGFPFNKWGK LKYAISARNRARTVAGY PHLMGWDYPKCDRAM GGTSSGDATTATANGVPNICQAVTANVNALLST FSMMILSDDAVVCFN ASQGLVASI
HKU3 DKSAGEPFNKWGK LKXAISAKRNRARTVAGY PHLMGWDYPKCDRAM GOTSSGDATTAYANSVPNICQAVTANVNALLST FSMMILSDDAVVCIN AAQGLVASI
SARS-COV DKSAGFPFNEWGK LKYAISAKNRARTVAGY PHLMGWDYPKCDRAM GGTSSGDATTAYANSVFNICQAVTANVNALLST FSMMILSDDAVVCYN AAQGLVASI
SHCO14 DKSAGFPFNKWGK LKYAISAKNRARTVAGY PHLMGWDYPKCDRAM GOTSSGDATTA'
ISVFNICOAVTANVNALLST FSMMILSDDAVVCYN AAQGLVASI
a
ee
f
I oe a
e
'560 612
ere
10 753
mee 711
Position in SARS-CoV i
V553.
in MHV and VSS:
SARS-CoV in Mont F
Sheahan et al., Nature Communications 11, 222 (2020)
Sheahan et al., Sci Trans! M